Publicidad
Editorial 20 de octubre de 2012

Terapia ablativa con yodo-131: juicio crítico de la evidencia. ¿Tiempo de cambiar paradigmas?

Referenciar Imprimir Descargar PDF

Referencias

  1. Schlumberger M, Catargi B, Borget I, et al. Strategies in radioiodine ablation in patients with low-risk thyroid cancer. N Eng J Med 2012;366:1663-73.
  2. Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Eng J Med 2012;366:1674-85.
  3. Alexander EK, Larsen PR. Radioiodine for thyroid cancer - Is less more? (Editorial). N Eng J Med 2012;366:1732-3.
  4. Sawka A, Thabane L, Parlea L, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: A systematic review and meta-analysis. Thyroid 2009;19:451-7.
  5. Iyer NG, Morris L, Tuttle M, et al. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 2011;117:4439-46.
  6. Kukulska A, Krajewska J, Gawkowska-Suwińska M, et al. Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi. Thyroid Research 2010;3:9
  7. Schvartz C, Bonnetain F, Dabakuyo S, et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab 2012;97:1526-35.
  8. Mazzaferri E, Jhiang S. Long-term impact of initial surgical and medical therapy on papillaty and follicular thyroid cancer. Am J Med 1994;97:418-28.
  9. Hay I, Thompson G, Grant C, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940 –1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002;26: 879-85.
  10. Sawka A, Brierley J, Tsang R, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin N Am 2008;37:457-80.
  11. Radioiodine ablation in low-risk thyroid cancer (Correspondence). N Eng J Med 2012;367:672-5.
  12. Bal C, Kumar A and Pant G. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: A randomized clinical trial in 509 patients. J Clin Endocrinol Metab 2004;89:1666-73.
  13. Bal C, Padhy A, Jana S, et al. Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996;77:74-80.